Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer

26 Feb 2018

Abstract excerpt

The somatic activation of PI3K/AKT pathway mutations, PIK3CA and AKT1, and ESR1 mutations in plasma cell-free DNA (cfDNA) has been studied as a non-invasive procedure to quickly assess and monitor disease progression or therapeutic effect in breast cancer (BC) patients, but the clinical significance of these mutations in late treatment lines (TLs) remains unclear. The subjects of this study were a total of 251...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to BRCA gene mutations in cancer
Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29482551
DOI: 10.1186/s12943-018-0808-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancerPMID 29482551Read ↗

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patientsSemantic proximity Read ↗

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.Semantic proximity Read ↗

Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.Semantic proximity Read ↗

ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.Semantic proximity Read ↗

Coupling multiplex pre-amplification and droplet digital PCR for longitudinal monitoring of <i>ESR1</i> and <i>PIK3CA</i> mutations from plasma cell-free DNASemantic proximity Read ↗

Detection of cancer DNA in plasma of patients with early-stage breast cancer.Semantic proximity Read ↗

Comparative Performance of a Targeted Next-Generation Sequencing Assay Against Multiplexed Digital PCR Assays in Detecting ERBB2, ESR1, and PIK3CA Mutations in Plasma Circulating Cell-Free DNA from Liquid Biopsies.Semantic proximity Read ↗

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Semantic proximity Read ↗

Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAsSemantic proximity Read ↗

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.Semantic proximity Read ↗

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.Semantic proximity Read ↗

ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.